Brought to you by:
Boston Scientific recalls Vici SDS and Vici RDS venous stent systems following reports of stent migration
According to a medical device recall notice posted on the Food and Drug Administration (FDA) website, Boston Scientific has recalled its Vici venous stent system (Vici SDS) and Vici RDS venous stent system due to reported instances of stent migration.…
Former SAVS president David Rosenthal dies at 76
Renowned vascular surgeon David Rosenthal, MD, co-founder of the Atlanta Vascular Society and a former president of both the Southern Association for Vascular Society (SAVS) and the Georgia Vascular Society, has died. He was 76. Beginning practice in Atlanta in…
One-year results from PROMISE I study of LimFlow system in ‘no-option’ CLTI patients published
Twelve-month data from the full patient cohort in the PROMISE I study of the LimFlow percutaneous deep vein arterialization (pDVA) system have been published in the Journal of Vascular Surgery. Results showed sustained positive outcomes for both amputation-free survival and…
Candidates for 2021-22 SVS vice president revealed
The candidates in the running to be the next Society for Vascular Surgery (SVS) vice president—and a future SVS president—have been unveiled. They are William Shutze, MD, and Joseph Mills, MD, both of whom operate in Texas and who, respectively,…
ACC.21: SAFE-PAD finds no increased risk of death with drug-coated devices
Researchers have found no statistically significant difference in mortality between patients treated with drug-coated devices and non-drug-coated devices in the SAFE-PAD study. Eric Secemsky, MD, an interventional cardiologist at Beth Israel Deaconess Medical Center (BIDMC) in Boston, reported this conclusion…
ACC.21: VOYAGER PAD shows rivaroxaban ‘significantly’ reduced total ischemic events in PAD patients
Rivaroxaban combined with low-dose aspirin led to a significant reduction in the occurrence of total ischemic events in patients with symptomatic peripheral arterial disease (PAD) who underwent lower-extremity revascularization, according to researchers conducting the VOYAGER PAD trial. The findings were…
In the room: Changes aplenty as VAM returns
The Vascular Annual Meeting (VAM) is more anticipated than ever after the annus horribilis of 2020 and the pared-back, digital VAM alternative that was SVS ONLINE. While organizers have previously relayed the changes made for this year’s meeting, Program Committee…
Intermittent claudication and exercise therapy: A poor SET-up
Many of you may have already heard about the controversial Comparative Billing Reports (CBRs) that have been received by some of our vascular surgery colleagues. In case you haven’t, this is your chance to catch up and to prepare for…
In brief: Spotlight
Ravi Chandra, MD, of Ocala, Florida, has been appointed to the Florida Board of Medicine, subject to Florida Senate confirmation. Peter McDonnell, MD, 65, Oak Park, Illinois, died March 20, of injuries he received in a bicycle-car accident March 9.…
TCAR vs CEA: Research shows fewer myocardial infarctions after TCAR with use of general anesthesia
A Vascular Quality Initiative (VQI) analysis uncovered a reduction in the risk of myocardial infarction after transcarotid artery revascularization (TCAR) compared to carotid endarterectomy (CEA) when general anesthesia is used—an observation mainly found in patients with symptomatic carotid artery stenosis.…